
Ansa Biotechnologies, the Emeryville-based DNA synthesis company, has closed a $71.5 million oversubscribed Series C financing round, pushing its total funding to $211 million. The round brings new backers including Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital, alongside returning investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
The financing was led by Blue Water Life Science Advisors, according to Business Wire. Ansa, which uses a proprietary enzymatic DNA synthesis platform, provides long, complex synthetic DNA with a guaranteed ship date, and its technology supports work in drug discovery, cell and gene therapies, vaccines, and agrigenomics.
As part of the round, the company is also reshaping its board. Nick Naclerio, who previously served as senior vice president of corporate and venture development at Illumina, and Brad Crutchfield, a former chief commercial officer at 10x Genomics and president of Bio-Rad Laboratories' life science group who also held leadership roles at Qiagen and Illumina, have both joined as directors. Nate Cornell, founder of Blue Water Life Science Advisors with more than 25 years of capital markets experience — including stints as director of research at PWP and senior equity research analyst at Pacific Growth Equities — has also joined the board. Rowan Chapman, co-founder of BEVC who previously held leadership roles at Johnson & Johnson, GE Ventures, and GE Healthcare, is joining as a board observer. Matthew McManus has stepped down from the board.
Why Investors Are Betting Big on Longer DNA
Ansa says the surge in demand stems from AI-enabled drug discovery and biological design, which is driving researchers to seek longer and more complex DNA sequences than conventional synthesis technologies can reliably deliver. The company says it has quadrupled its manufacturing capacity during the past year to keep pace. CEO Jason T. Gammack said the company's growth reflects demand for reliable access to sequences that previously held projects back, per Business Wire.
That bottleneck isn't unique to Ansa's pitch. A separate Fierce Biotech report on the company's earlier fundraising described the ability to write long and complex DNA as a critical bottleneck across the broader life sciences industry, a view attributed to Northpond Ventures principal Lily Li. The same report noted that Ansa's method binds nucleotides to a DNA polymerase before adding them to a sequence, which the company says allows for faster, more cost-effective synthesis than other enzymatic approaches that add modified nucleotides one at a time.
Nick Naclerio said the new backing lets researchers access historically difficult DNA with a delivery commitment they can plan around, while Nate Cornell said the financing will help Ansa expand its capabilities and scale operations to meet customer demand, according to the Business Wire release.
A Guarantee Built Around Speed
Central to Ansa's pitch is its On-Time Guarantee, which promises customers a committed ship date — and the entire order free if that date is missed. The company offers sequence-perfect clonal DNA up to 50 kilobases as well as sequence-verified linear double-stranded DNA fragments, and it screens all orders for biosecurity.
That guarantee dates back to the company's Series B financing, a $54.4 million round announced in a separate Business Wire release, which included $45.2 million closed and an additional $9.2 million in commitments. That round, led by Cerberus Ventures with participation from Blue Water Life Science Advisors and Altitude Life Science Ventures, was pitched as funding to expand Ansa's U.S.-based manufacturing capacity and deepen its focus on customer experience, strategic relationships, and technological innovation. At the time, Ansa said it could deliver 50 kilobases of clonal DNA in 24 days or less — service promised on time or it's free.
Ansa's earlier Series A round, an oversubscribed $68 million raise led by Northpond Ventures, had already pushed the company's lifetime fundraising total past $80 million at the time, Fierce Biotech reported.
An Industry Racing to Keep Up With Demand
The broader synthetic DNA market has been grappling with capacity constraints for years. A Forbes report noted that demand for synthetic DNA products has been growing steadily, with customers sometimes waiting weeks to receive their orders. That same report said standard DNA services are generally capped at 150 base pairs, while enzymatic synthesis methods don't carry that length limitation.
Other players have moved to address the gap. San Diego-based Molecular Assemblies began shipping enzymatically synthesized DNA to customers from a newly opened facility and had launched a Key Customer Program following a $28.5 million Series B round, per the Forbes report. Ansa's media contact is listed as Andrew Noble.









